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Abstract
Fish oil contains omega-3 as an anti-inflammatory effect that can inhibit the production of arachidonic acid 
5-lipoxygenase (ALOX5), an enzyme that aggravates the inflammation of the lungs that cause asthma. This study 
aims to determine the effect of omega-3 from fish oil on improving lung function with peak expiratory flow (PEF) 
value in patients with outpatient asthma in Surabaya. The research design used in this research is pre-post test 
design and lung function examination by using a peak flow meter. Then follow up every week for four weeks during 
the use of fish oil, and the results of his research were analyzed by t test. The study was conducted from April 2017 
until January 2018 in Surabaya. The sample of the study was 27 adult asthma patients. The results showed that 
most of the study subjects had an increase in PEF value every week. Besides, there was a significant increase of PEF 
values gradually at T0 (before intervention) to T4 (intervention for four weeks), indicating an improved effect after 
the use of fish oil in a four-week study sample. In conclusion, fish oil containing omega-3 is effective in improving 
lung function in outpatient asthma patients.
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Pilot Studi Perbaikan Fungsi Paru menurut Nilai Peak Expiratory 
Flow (PEF) Menggunakan Terapi Minyak Ikan Mengandung 
Omega-3 pada Asma
Abstrak
Minyak ikan mengandung omega-3 sebagai efek antiinflamasi yang dapat menghambat produksi asam arakidonat 
5-lipoksigenase (ALOX5) merupakan enzim yang memperburuk peradangan paru yang menyebabkan asma. 
Penelitian ini bertujuan mengetahui pengaruh omega-3 dari minyak ikan terhadap perbaikan fungsi paru 
dengan nilai peak expiratory flow (PEF) pada pasien asma dewasa rawat jalan di Surabaya. Desain penelitian 
yang digunakan dalam penelitian ini adalah pre-post test dan pemeriksaan fungsi paru menggunakan peak flow 
meter. Kemudian dilakukan follow up setiap minggu selama empat minggu selama penggunaan minyak ikan dan 
hasilnya dianalisis dengan uji t. Penelitian dilakukan pada April 2017 hingga Januari 2018 di Surabaya. Sampel 
penelitian sebanyak 27 pasien asma dewasa. Hasil penelitian menunjukkan bahwa sebagian besar subjek penelitian 
mengalami peningkatan nilai PEF setiap minggunya. Selain itu, terdapat peningkatan signifikan nilai PEF secara 
bertahap pada T0 (sebelum intervensi) sampai T4 (intervensi selama empat minggu) yang menunjukkan efek 
membaik setelah penggunaan minyak ikan pada sampel penelitian selama empat minggu. Simpulan, minyak ikan 
yang mengandung omega-3 terbukti efektif dalam perbaikan fungsi paru pada pasien asma rawat jalan..
Kata kunci: Asma, minyak ikan, omega-3, peak expiratory flow
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Introduction
Asthma is defined as chronic inflammation of 
the airways, with respiratory symptoms such as 
wheezing, shortness of breath, chest tightness, 
and coughing that vary over time and intensity, 
together with variable limitations of expiratory 
airflow.1 The Ministry of Health estimates that 
asthma is among the top 10 causes of illness and 
death in hospitals.2 According to Global Burden 
data, asthma has increased and is now ranked 
28th as a disease that affects one's adjusted-life 
year.3 Adverse effects of asthma include decreased 
quality of life, decreased productivity, absence 
from school, increased health costs, increased 
risk of hospitalization, and even death.4
The treatment has now shifted from synthetic 
drugs to nutritional treatments. Therapy with 
synthetic drugs still often causes drug-related 
problems, both in drug selection, difficulties 
in using tools, the emergence of side effects, to 
the cost burden that is greater than it should 
be.5–12 Lifestyle consumption of nutrients plays 
an essential role in developing several diseases, 
including inflammatory diseases as a cause 
of asthma.5 Consumption of fish can prevent 
asthma in adult patients. Research shows that 
fish consumption at least once a month, can 
reduce the risk of asthma.13 Populations with 
high intakes of fish also have low levels of asthma. 
This theory states that fish oil content can reduce 
inflammation that causes swelling in the lung 
channels leading to asthma attacks.14 Fish oil 
is a very effective nutrient containing essential 
omega-3 fatty acids and can be absorbed easily. 
Fish oil contains docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA).13 Omega-3 
contained in fish oil is considered a potential 
therapy for asthma and other inflammatory 
diseases. Fish oil inhibits the production of 
arachidonic acid 5-lipoxygenase (ALOX5), an 
enzyme that exacerbates inflammation of the 
lungs that causes asthma.15
Indonesia, a maritime country, has excellent 
fish production potential, which can process fish 
oil, such as salmon, cod, etc. Meanwhile, several 
studies related to fish oil have also been carried 
out, which contain omega-3 as conducted by 
Aprizayanti,16 and Santoso et al.17 However, there 
are no studies related to the effect of omega-3 
in fish oil on asthma improvement. Control of 
asthma symptoms is also related to the limitations 
of the expiratory airflow variable. The function of 
lung expiration varies from time to time and is 
more significant than in healthy populations.1 
Many methods for assessing lung physiology 
have been widely accepted as a standard. It 
is spirometry and peak expiratory flow (PEF) 
examinations. PEF self-monitoring can be useful 
in asthma management, especially in those 
with low perceptions of their airways.12 Peak 
expiratory flow has a unique role in the initial 
investigation of asthma work, where pulmonary 
testing functions are often needed.18
Hopefully, this research can improve 
knowledge related to the nutrition of asthma. 
Also, pharmacists' role supports the management 
of asthma and provides information, counseling, 
and education. So, they better understand the 
treatment regimen given so patients can play an 
active role in their treatment, improving their 
compliance with the drug. In the integrated 
team, the pharmacist's role is to provide 
recommendations in the selection of appropriate 
drugs based on the patient's condition obtained 
from the results of the interview and the results 
of the doctor's diagnosis.4 This study aims to 
determine the effect of omega-3 from fish oil on 
lung function improvement with PEF values in 
outpatient adult asthma patients in Surabaya.
Methods
The research design was the pre-post test design, 
examining lung function using a peak flow meter. 
The study was conducted from April 2017 until 
January 2018, with ethical tests that have been 
conducted and get number 004/KE/I/2017 at the 
Institutional  Ethical Committee of the University 
of Surabaya. The composition in fish oil given was 
1000 mg omega-3, 180 mg EPA, 120 mg DHA. 
Fish oil was given to patients and then followed 
up every week for four weeks with a once-daily 
dose that was proven to consume fish oil at least 
once a month can reduce the risk of asthma, with 
a dose of 1 gram to 5.4 grams per day.19 So, in this 
study, selected fish oil with a dose of 1.0 gram.
This study's variable was the value of PEF in 
outpatient asthma patients. The peak flow meter 
was a measure of PEF. Peak expiratory flow 
(PEF) can indicate the degree of limited airflow. 
For each type of peak flow meter, the PEF value 
obtained was also different. Respondents were 
asked to measure lung function's value using a 
peak flow meter 3 times and see the best value. 
Measurement using a peak flow meter was 
performed by patients with the researchers' 
assistance six times in 6 weeks after consuming 
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fish oil for one week.
The study population was outpatient asthma 
patients. The research sample was with the 
following inclusion criteria were adults age 18–
45 years, and patients were willing to participate 
in the study voluntarily after receiving informed 
consent. Exclusion criteria: (1) having a disease 
that can affect the data collection process requires 
a differential diagnosis. These diseases include 
bronchitis, chronic obstructive pulmonary 
disease (COPD), sinusitis, vocal cord dysfunction, 
bronchiectasis, heart disease, alpha1 deficiency-
antitrypsin, pulmonary embolism, and kidney 
disorders. It also excludes patients, which is (2) 
smoking or stopping smoking <2 years, and (3) 
patients who used routine asthma medication 
(controller). The research subjects were obtained 
by purposive sampling method.
A paired t test was used to determine the 
presence or absence of an average difference 
between 2 groups of related samples. One sample 
underwent two different treatments. Test the 
difference between observations before and after 
therapy, using paired t test. This pooled t test was 
used to determine whether there was an average 
difference between the two unrelated sample 
groups. Test the difference between observing 
PEF values at week 0 and week 4 in patients 
receiving fish oil therapy.
Results
In Table 1, explaining the number of samples 
(subjects) of male research was less than female 
respondents, with most ages ranging from 17–25 
years. Most subjects (10 of 27) used a short-
acting beta-2 agonist by the inhalation route 
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Table 2 Changes in Peak Expiratory Flow Value After Giving Fish Oil Therapy
Groups being Compared
Frequency of Subjects Changing PEF Value  (L/sec)
Increased Fixed Decreased
T0 and T1 20 2 5
T0 and T2 21 1 5
T0 and T3 20 1 6
T0 and T4 24 1 2
T1 and T2 20 0 7
T2 and T3 16 2 9
T3 and T4 21 0 6
Note: PEF=peak expiratory flow; T0=week 0, the study sample has not received the intervention; T1=in the first week, the test 
group's research sample had received the intervention (fish oil) for one week; T2=in the 2nd week, the test group sample had 
received the intervention (fish oil) for two weeks; T3=in the 3rd week, the test group's research sample had received the intervention 
(fish oil) for three weeks; T4=in the 4th week, the test group's study sample had received the intervention (fish oil) for four weeks
Figure Peak Flow Meter
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(salbutamol MDI) as asthma therapy was used 
only when asthma symptoms appeared.
Most research subjects experienced an 
increase every week after the use of fish oil (Table 
2). In Table 3, it was known that there was an 
increase in PEF values at T0 to T4. It showed 
an improved effect after the use of fish oil in 
the study sample for four weeks. However, the 
increase did not occur similarly every week. T2–
T1 had an average increase of 22.41 L/sec, T3–T2 
had an average increase of 3.33 L/sec, and T4–T3 
had an average increase of 26.11 L/sec.
The normality test used Shapiro-Wilk 
because of the number of samples <50 subjects. 
Normality tests regarding the research samples' 
PEF values at T0, T1, T2, T3, and T4 found 
that T1, T2, T3, and T4 groups were normally 
distributed (p>0.05). However, the t0 group 
was not normally distributed (non-parametric) 
(p<0.05, Table 4).
The normality test in Tabel 4 used a paired t 
test if it is normally distributed while a normally 
distributed Wilcoxon signed-rank test is used. 
Table 5 showed that there was a significant 
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Table 3 Average Peak Expiratory Flow Values
Average (x̄) 
Changes in PEF Values from Before 











Changes in PEF values from Before 










T0 217.96 x̄T1–T0= 
55.19T1 273.15 x̄T2–T1= 
22.41T2 295.56 x̄T3–T2= 
3.33T3 298.89 x̄T4–T3= 
26.11T4 325.00
Conclusion: all experienced an increase 
in PEF values after 4 weeks on average 
by 107.04
Conclusion: all have increased but the 
numbers are not significant every week
Note: PEF=peak expiratory flow; T0=week 0, the study sample has not received the intervention; T1=in the first week, the test 
group's research sample had received the intervention (fish oil) for one week; T2=in the 2nd week, the test group sample had 
received the intervention (fish oil) for two weeks; T3=in the 3rd week, the test group's research sample had received the intervention 
(fish oil) for three weeks; T4=in the 4th week, the test group's study sample had received the intervention (fish oil) for four weeks








Note: *Shapiro-Wilk test; T0=week 0, the study sample has 
not received the intervention; T1=in the first week, the test 
group's research sample had received the intervention (fish 
oil) for one week; T2=in the 2nd week, the test group sample 
had received the intervention (fish oil) for two weeks; T3=in 
the 3rd week, the test group's research sample had received 
the intervention (fish oil) for three weeks; T4=in the 4th week, 
the test group's study sample had received the intervention 
(fish oil) for four weeks; p>0.05 means normal distribution 
and p<0.05 means that the distribution is not normal
Table 5 Statistical Tests of Peak 
Expiratory Flow Intervention 
Groups by Ratio Scale
Groups p Value
T0 and T1 0.014*
T0 and T2 0.003*
T0 and T3 0.009*
T0 and T4 0.000*
T1 and T2 0.000**
T2 and T3 0.013**
T3 and T4 0.017**
Note: *Wilcoxon signed-rank test; **paired t test; T0=week 
0, the study sample has not received the intervention; T1=in 
the first week, the test group's research sample had received 
the intervention (fish oil) for one week; T2=in the 2nd week, 
the test group sample had received the intervention (fish oil) 
for two weeks; T3=in the 3rd week, the test group's research 
sample had received the intervention (fish oil) for three 
weeks; T4=in the 4th week, the test group's study sample had 
received the intervention (fish oil) for four weeks; p>0.05: Ho 
is rejected, meaning there is no significant difference; p<0.05: 
Ho accepted means that there are significant differences
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increase every week in the PEF values of study 
subjects. The most significant increase occurred 
in the first week (T1) of fish oil administration 
compared to before therapy (T0,  Table 3).
Discussion
The PEF value estimated the peak expiratory rate. 
It is the fastest measure of airspeed exhaled by 
the lungs after inhaling a long breath expressed 
in units of liters per second (L/sec). Peak flow 
meters were used to assess the PEF. The peak flow 
in patients may show changes before the patient 
experiences an exacerbation.20 Previous studies 
using PEF values as clinical outcomes for asthma 
therapy have been conducted by Burkhart et al.,21 
Harrison et al.,22 and Ramsay et al.23
Table 2 showed an increase in PEF values 
at T0 to T4, indicating an improved effect after 
using fish oil in the study sample for four weeks. 
Table 5 showed a significant change every week, 
but the increase does not occur the same every 
week. It was due to several factors that can affect 
the PEF value, such as differences in activity and 
weather every week that cannot be controlled. The 
researcher cannot control the activity because 
the study sample is a student who has a dense 
activity. Besides that, the research is also carried 
out during the rainy season, which can increase 
the research sample's sensitivity so that it causes 
the emergence of asthma exacerbations.
It was also strengthened by the results of 
statistical analysis test results of PEF values 
between T0, T1, T2, T3, T4, and K1, which have 
p=0.000 (p<0.005) then Ho was accepted, 
meaning that the value of PEF after the use 
of fish oil was significantly different statistics. 
Researchers choose four weeks as the minimum 
time for fish oil intervention because a previous 
study stated that fish oil's effects appeared 
after a minimum consumption of 4 weeks. 
However, there was no further research if fish 
oil is consumed for more than four weeks. It was 
expected that further research would be on the 
effect of improving PEF values after fish oil use 
for more than four weeks.
Several factors affect the PEF value and can be 
controlled by researchers, such as food and drugs 
consumed by research subjects. Control of this 
factor is done by providing a logbook containing a 
list of foods and medicines consumed daily by the 
study sample for four weeks of research. Factors 
characteristic of the study sample that can affect 
the PEF value include gender, physical activity, 
nutrition/food intake, asthma treatment used, 
occupation, and lung function.
According to Zein and Erzurum,24 in women, 
the influence of estrogen and progesterone 
hormones cause a high risk of asthma during 
and after puberty. Asthma is, therefore, more 
common in women after puberty compared 
to men.1 The same thing was expressed by the 
Center for Disease Control and Prevention (CDC) 
in 2016, which said that women's prevalence was 
higher than men's.25 Respondents in this study 
were teenagers aged 17–25 years at 96.15%, 
early adulthood 41–60 years at 3.85%, and late 
adulthood at 36–45 years at 0%.
Exercise-induced asthma is a symptom of 
asthma that arises in non-asthmatic patients due 
to excessive physical activity. When someone 
is doing strenuous physical activity, they will 
breathe more, faster through the mouth. It then 
causes the air that enters the lungs to be colder 
and drier than normal air. A bronchial membrane 
in the lungs can swell, which then appears asthma 
symptoms such as wheezing. Exercise-induced 
asthma generally occurs in winter.26 Entertaining 
physical activity classified as heavy can trigger an 
exacerbation in patients with asthma that is not 
controlled. Some also suffer from exacerbations 
only during physical activity.1
The appearance of asthma symptoms can 
be related to food chemicals that can cause 
individual reactions. It is related to a person's 
level of intolerance.1
Outpatient asthma treatment is divided 
into two, namely the controller and reliever. 
The controller is a treatment used daily in the 
long term to keep asthma under clinical control 
through its anti-inflammatory effects. Whereas 
reliever is a treatment used when necessary 
and quickly to reduce bronchoconstriction and 
reduce the acute symptoms that accompany it.1 In 
this study, all respondents were in step 1, which 
means that none of the respondents used a type 
of asthma control controller to maintain asthma 
control daily. All respondents only used asthma 
reliever when experiencing worsening symptoms 
(reliever). This type of reliever's primary 
choice is short-acting beta-2 agonist (SABA), 
which is generally salbutamol by the route of 
inhalation administration. The inhalation route 
is preferred because it is topical, so side effects 
tend to be smaller and can work directly to the 
bronchioles' target site.1 However, from the 
Amelia Lorensia et al.: Pilot Study of Lung Function Improvement in Peak Expiratory Flow (PEF) Value Using Fish Oil
Global Medical and Health Communication, Volume 8 Number 3, December 2020
216
respondents' treatment data, some respondents 
use corticosteroids (oral or inhalation) and 
methylxanthine group, which is an asthma 
therapy in the controller group.
In this study, 26 subjects were taken as 
respondents who have jobs as students (100%). 
Wijnhoven et al.,27 in their study, stated that 
asthma patients with a higher level of education 
had a better quality of life than asthma patients 
with a lower level of education.Therefore, in this 
study, the work factor involves respondents who 
have status as students.
Measurement of lung function in this study 
assesses PEF with peak flow meters of the 
same type and brand. The condition of patients 
experiencing asthma exacerbations also affects 
the ability of research subjects when blowing 
peak flow meters. The amount of air will 
influence the device breathed (inspiration) and 
the amount of air exhaled (expiration). Whereas 
when patients have asthma exacerbations, the 
patient experiences impaired limitations in 
expiration.1 Also, other factors can influence 
PEF measurements, such as body weight and 
socioeconomic status.
In this study, the best value prediction 
examination was not carried out because the 
patient first used the device and could not get the 
patient's height due to the condition or condition 
of the patient, which made it impossible to 
measure height in patients who had asthma 
exacerbations in the emergency room, so the 
predictive value in patients using the average 
height of Indonesians, namely for men at 162.5 
cm and women 151.2 cm.28
There are still weaknesses and shortcomings 
in conducting research, although researchers 
have tried their best to make the research results 
perfect. Researchers realize that the study's 
limitations include: (1) respondents' inclusion 
criteria such as heart and kidney history data 
were not obtained accurately. Because when the 
respondent said that there was no history of heart 
and kidney, it was not supported by checking the 
doctor first by using an electrocardiogram (EKG); 
(2) the type of fish oil used in this study is fish 
oil from abroad. Researchers used this type of 
fish oil because the dose was by the desired fish 
oil dose of 1.0 gram. Therefore respondents felt 
uncomfortable consuming fish oil, which was 
considered quite large because some respondents 
commented on the large soft capsule; and (3) there 
are time variations that can affect PEF values. 
The PEF value variability depends on the diurnal 
cycle (morning and evening values are different), 
and the expected value of this variability <20%.1,4
Conclusion
Fish oil containing omega-3 effectively increases 
lung function every week in asthma patients, 
from the first week of therapy to the fourth week.
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